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Abstract
a-Synuclein (aSN) in human is tightly linked both neuropathologically and genetically to Parkinson’s disease (PD) and
related disorders. Disease-causing properties in vivo of the wildtype mouse ortholog (maSN), which carries a threonine at
position 53 like the A53T human mutant version that is genetically linked to PD, were never reported. To this end we
generated mouse lines that express maSN in central neurons at levels reaching up to six-fold compared to endogenous
maSN. Unlike transgenic mice expressing human wildtype or mutant forms of aSN, these maSN transgenic mice showed
pronounced ubiquitin immunopathology in spinal cord and brainstem. Isoelectric separation of maSN species revealed
multiple isoforms including two Ser129-phosphorylated species in the most severely affected brain regions. Neuronal
Ser129-phosphorylated aSN occured in granular and small fibrillar aggregates and pathological staining patterns in neurites
occasionally revealed a striking ladder of small alternating segments staining either for Ser129-phosphorylated aSN or
ubiquitin but not both. Axonal degeneration in long white matter tracts of the spinal cord, with breakdown of myelin
sheaths and degeneration of neuromuscular junctions with loss of integrity of the presynaptic neurofilament network in
maSN transgenic mice, was similar to what we have reported for mice expressing human aSN wildtype or mutant forms. In
hippocampal neurons, the maSN protein accumulated and was phosphorylated but these neurons showed no ubiquitin
immunopathology. In contrast to the early-onset motor abnormalities and muscle weakness observed in mice expressing
human aSN, maSN transgenic mice displayed only end-stage phenotypic alterations that manifested alongside with
neuropathology. Altogether these findings show that increased levels of wildtype maSN does not induce early-onset
behavior changes, but drives end-stage pathophysiological changes in murine neurons that are strikingly similar to those
evoked by expression of human wildtype or mutant forms.
Citation: Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, et al. (2011) Neuropathology in Mice Expressing Mouse Alpha-Synuclein. PLoS ONE 6(9): e24834.
doi:10.1371/journal.pone.0024834
Editor: Koichi M. Iijima, Thomas Jefferson University, United States of America
Received June 15, 2011; Accepted August 22, 2011; Published September 26, 2011
Copyright:  2011 Rieker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Novartis Pharma AG, who, through the employment of Claus Rieker, Katja Lehnhoff, Samuel Barbieri, Sabine Kauffmann,
Simone Danner Herman van der Putten and Derya Shimshek, had a role in conceiving, designing and performing the experiments and analyzing the data.
Competing Interests: Claus Rieker, Katja Lehnhoff, Samuel Barbieri, Sabine Kauffmann, Simone Danner Herman van der Putten and Derya Shimshek are
employees of Novartis Pharma AG. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to
all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: derya.shimshek@novartis.com
¤ Current address: Department of Neuroscience, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
Introduction
Disorders collectively referred to as the a-synucleinopathies
include a number of clinically diverse neurodegenerative diseases
that constitute a critical biomedical problem. Prevalent a-synuclei-
nopathies include idiopathic Parkinson’s disease (iPD), dementia
with Lewy bodies (DLB) (7–30% dementia in elderly), the Lewy
body variant of Alzheimer’s disease (LBVAD) with rare forms in
some familial forms of PD (fPD), the familial form of AD and Down
syndrome, multiple systems atrophy (MSA), Hallervorden-Spatz
disease (HSD), neurodegeneration with brain iron accumulation
type-1 (NBIA-1), Niemann-Pick Type C Disease (NPC), parkinson-
ism–dementia complex of Guam (PDC-Guam), diffuse neurofibril-
lary tangles with calcification (DNTC) and pure autonomic failure
[1]. The common neuropathological hallmarks in neurons and glia
are microscopic proteinaceous inclusions, composed mainly of
aggregated fibrillar alpha-synuclein (aSN). aSN is an abundant
presynaptic protein in the brain. Its 140 amino-acid sequence is
highlyhomologousacrosshuman, rat and mouse (for review see[2]).
Initially, aSN microscopic aggregates were postulated to play a key
role in the pathophysiology of a-synucleinopathies. Neurotoxicity
findings implicate aSN protofibrils, soluble aSN protein complexes,
posttranslationally modified forms of aSN (in particular nitrosy-
lated), phosphorylated at serine 129 (Ser129), as well as mono- and
di-ubiquitinated aSN forms [3]. In DLB brains more than 90% of
the insoluble aSN is phosphorylated at Ser129 compared to about
4% phosphorylated at Ser129 in brains of normal individuals.
Furthermore, Ser129 phosphorylated aSN is targeted to mono- and
di-ubiquitination in a-synucleinopathy brains [4]. Extensive phos-
phorylation at Ser129 and/or its mono- and di-ubiquitination are
critical events in the pathophysiology of aSN. However, direct
experimental evidence supporting this notion is lacking and it is still
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24834debated whether these molecular forms of aSN are on the critical
pathophysiological path rather than representing molecular epiphe-
nomena of the disease process.
As multiple toxic mechanism have been proposed for aSN, it is
important to determine which of its molecular forms are on the
critical pathophysiological path. One main hypothesis of aSN
toxicity is based on its capability to form toxic oligomers. Familial
forms of Parkinson’s disease possess mutant forms of aSN A53T
and A30P (and E46K) that form oligomers more rapidly than
wildtype aSN. In idiopathic forms of a-synucleinopathies that lack
heritable aSN mutations, it is speculated that compromised
handling of aSN and/or specifically modified forms are hamper-
ing aSN catabolism as well as that of other proteins. Oxidative
damage of aSN could change aSN into toxic forms that trigger
such a pathophysiological cascade [3].
It is unclear how critical to the disease process are some of the
differences in aSN amino-acid sequence between human, rat and
mouse. There is no solid evidence for endogenous mouse aSN co-
aggregating with human aSN expressed in transgenic rodent
models [5,6,7,8,9]. Furthermore, non-fibrillar aSN neuropathology
in brain regions of human aSN transgenic mice is prominent also in
regions where neurons express little or no endogenous mouse aSN
[6,7]. Some transgenic mouse models develop human-like fibrillar
aSN structures and this may to a large extent depend on the
transgene expression cassette that is used [7]. Thus, it appears that
aSN pathology in transgenic species varies and is influenced by a
number of experimental and endogenous factors. Knowing these
factors could shed more light on genetic and environmental risk
factors associated with diseases involving aSN. In an attempt to
resolve some of these questions we generated transgenic mice over-
expressing murine wildtype aSN driven by the Thy1 regulatory
sequences enabling a direct comparison with previous human aSN
transgenic lines generated previously in our laboratory [6].
Results
High expression of maSN mRNA and protein levels in the
Thy1-maSN transgenic mouse line
Three transgenic C57BL/6 mouse lines were produced that
express different levels of the Thy1-mouse aSN (maSN) transgene
(Figure 1A). Two lines 1S14 and 1S16 had comparable low levels
whilst the third line 1S13 expressed transgene mRNA (Figure 1B
upper part) and protein (Figure 1B lower part) levels in brain
that were up to 6-fold above endogenous aSN in wildtype mice as
shown by quantification in Figure 1C. Transgene mRNA levels
in 1S13 mouse line were comparable to those in two lines
described previously, expressing the A53T fPD and wildtype form
of human aSN (haSN) [6]. Our analyses described here focus on
the line 1S13 (named Thy1-maSN hereafter).
Similar to the Thy1-haSN mouse lines [6], expression of Thy1-
maSN transgene mRNA and maSN protein in Thy1-maSN
mouse brain was widespread. This is illustrated by in situ
hybridization (Figure 1D) and aSN protein immunohistochem-
istry (Figure 1E) in low-magnification sagittal brain sections from
Thy1-maSN (aSN knock-out (KO) mouse brains served as a
negative control). The overall expression pattern of the transgene
in Thy1-maSN was also very similar to those reported for the two
lines expressing haSN under the control Thy1 regulatory
sequences [6]. Interestingly there was no apparent weight loss in
Thy1-maSN mice until 6 months of age (Figure 1G) in contrast
to mice over-expressing haSN with an early-onset weight loss
(Figure S1A). Not until around 6–7 months of age Thy1-maSN
mice stopped gaining weight and in addition start to display severe
motor deficits. This is again in sharp contrast to Thy1-haSN mice
that showed early-onset impairments of motor performance
(Figure S1 and [6]). Furthermore we observed increased mortality
in Thy1-maSN mice compared to control wildtype (wt) littermates
(Figure 1H).
Overexpression of wildtype murine aSN leads to mild
impairment of motor performance
We performed different behavioral studies to determine motor
function. Thy1-maSN mice showed no difference in the open field
paradigm. Neither velocity (Figure 2A) nor total activity
(Figure 2B) was changed. Furthermore, no difference could be
detected in forelimb grip strength (Figure 2C). Motor coordina-
tion was assessed using the accelerated rotarod task starting at two
months of age. During the first four weeks, Thy1-maSN mice
showed impaired motor learning but by 12 weeks of age and after
a number of training sessions, the performance of Thy1-maSN
mice was indistinguishable from wt mice up to the age of six
months (Figure 2D). From 6–7 months onwards, a steady and
rapid decline in rotarod performance in Thy1-maSN mice
became obvious (Figure 2D). Interestingly no difference in
light/dark cycle activity, assessed by an actimeter for 48 h, could
be detected between Thy1-maSN and wt mice (Figure 2E). In
order to determine the anxiety of Thy1-maSN mice we performed
dark-light box and elevated plus maze experiments (Figure 2F,G).
We observed similar latencies and total time spend in the lit
compartment between wt and mutants in the dark-light box
(Figure 2F), suggesting no impact on anxiety. This was fortified
using the elevated plus maze (Figure 2G). It is remarkable that
Thy1-maSN mice displayed a late-onset and much less pro-
nounced motor impairment than transgenic mice expressing the
haSN transgene with early-onset (already at 5 weeks of age) and
steady decline in motor control (Figure S1 and [6]).
Perikaryal and neuritic accumulation of maSN
Similar to earlier observations in mice expressing haSN forms [6]
we found maSN expressed in many neurons in telencephalon,
hippocampus, brainstem, cerebellar nuclei and spinal cord
(Figure 1E). The maSN expression in the hippocampus showed
an increase in perikaryal and neuritic immunostaining for aSN and
cerebellar nuclei respectively (Figure S2). In a substantial neuronal
subset expression of the transgene was sufficient for perikaryal and
neuritic maSN accumulation, which did not change over time
(Figure S2).This is further demonstrated by maSNimmunostaining
of hippocampal neurons in mice expressing the Thy1-maSN
transgene on a mouse genetic background with a disrupted
endogenous aSN gene (aSN KO) (Figure S3D). The specificity of
the aSN immunostainings is illustrated by the very low levels of
background staining in aSN KO mouse brain sections (FigureS3C).
Prominent development of maSN pathology, axonal
degeneration and breakdown of myelin sheaths in spinal
cord and brainstem
Like Thy1-haSN mice [6], the Thy1-maSN mouse developed a
pronounced aSN pathology in spinal cord around the age of 6
months. We located prominent perikaryal and neuritic aSN
staining in sections through the anterior horn (Figure 3A,B) and
in addition strong ubiquitin immunoreactive motor neurons with
spindle-shaped dilated proximal dendrites (Figure 3C). Using an
antibody specific for the serine 129 phosphorylated form of aSN
(P-Ser129aSN), we found immunolabeling of motor neuron cell
bodies and presynaptic boutons in transgenic (Figure 3D) but not
wt mouse spinal cord (not shown). The P-Ser129aSN antibody
recognizes specifically a form of aSN that is phosphorylated at
Overexpression of Mouse Alpha-Synuclein
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diseased human and aSN transgenic brain, but not in normal
mouse brains [10].
Until recently aSN axonal pathology was grossly underestimated
although it is now documented in several of the transgenic animal
models [6,7,11,12,13]. In this current study, we found that motor
neuron pathology was accompanied by axonal pathology in spinal
cord white matter (Figure 3E–H). Immunostaining for ubiquitin
(Figure 3E), and Holmes-Luxol staining (Figure 3F) revealed
axonal degeneration in long white matter tracts of the spinal cord
withbreakdown of myelin sheaths into rowsof myelin ovoids. Many
axons in the cord and spinal roots were immunolabeled with aSN
antibody (Figure 3G). Central axons were often enlarged and a
subpopulationimmunolabeled withanti-P-ser129aSN (Figure3H)
which consistently left unstained the same tissue in wt mice (not
shown). Unlike in the transgenic lines expressing haSN [6],
ubiquitin immunopathology was detected in every single Thy1-
maSN mouse aged 6 months (see below).
The aSN histopathology in brainstem, cerebellum and spinal
cord was accompanied by prominent astrogliosis (Figure S4A–E),
microgliosis (IBA1-positive cells; Figure S4F–H) and axonal
degeneration (Campbell silver stainings; Figure S4I–K). Notably,
other brain areas including hippocampus, cortex, striatum and
thalamus showed little or none of these histopathological hallmarks
despite many neurons showing high aSN transgene expression in
these brain areas.
Synaptic defects in the neuromuscular junction
Aggregates and/or soluble forms of aSN are present in neuronal
somata and dendrites under pathological conditions in human and
Figure 1. Thy1-maSN and wildtype mice transgene expression. (A) Schematic diagram depicting wildtype murine aSN expression under the
control of Thy1 regulatory sequences. Roman numerals refer to murine Thy1 exons. A filled horizontal bar indicates the mouse aSN cDNA probe that
was used for northern and the cRNA probe used for in situ hybridization. (B) (upper part) Northern blot analysis of 10 mg total brain RNA per lane
showing wildtype (wt) and mice from the Thy1-maSN mouse founder lines 1S13, 1S14 and 1S16. (lower part) Immunoblot analysis using a
monoclonal anti-aSN antibody showing the highest over-expression of murine aSN protein in the founder line 1S13, as compared to wt, founder
mouse lines 1S14 and 1S16. (C) Quantification of over-expressed aSN protein in offsprings of the founder line 1S13 (+/T, black) compared to wt
(white). wt: n=7; +/T: n=13. Data are shown as mean 6 SD. (D) In situ hybridization in sagittal brain sections of a wt mouse, a Thy1-maSN (line 1S13)
and a aSN knock-out (KO) mouse. Probe was a
35S-labeled mouse aSN cRNA as represented by bar in Fig. 1A. (F) Free-floating sagittal whole brain
sections immunostained for murine aSN in wt, Thy1-maSN (line 1S13) and aSN KO mouse. (G) Body weight assessment in wt littermates (dotted,
n=12) and Thy1-maSN (+/T, black, n=10, line 1S13). (H) Thy1-maSN (+/T) transgene mice show increased mortality rate compared with wt
littermates (n=10). * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0024834.g001
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This contrasts with aSN being mainly presynaptic under normal
circumstances. With respect to adverse effects on the neuronal cell
in its entirety, it remains unclear whether pre- or post-synaptic
changes are compromised first. Interestingly, muscles contained
small angulated fibers reminiscent of neurogenic muscular atrophy
(Figure 3I). In addition, we found that neuromuscular synapses
showed signs of presynaptic degeneration although less pro-
nounced as reported previously in lines expressing haSN [6]. a-
Bungarotoxin staining patterns for postsynaptic acetylcholine
receptors were not different between wt and Thy1-maSN mice
(age 6 months) (Figure 3J,N), neither in soleus (slow-twitch,
Figure 3J–Q) nor extensor digitorum longus (EDL, fast-twitch)
muscles (not shown). Also, we detected little or no changes
between wt and transgenic mice in presynaptic synaptophysin
staining (Figure 3K,O). In contrast, staining of presynaptic
neurofilaments differed dramatically. The neuromuscular junc-
tions in Thy1-maSN mice showed thinning or absence (not shown)
of presynaptic neurofilament staining (Figure 3L,P). In summary,
neuromuscular junctions in Thy1-maSN mice showed degenera-
tion that was independent of muscle fiber type and similar, as
reported for mice expressing haSN transgene [6].
Phosphorylated aSN is expressed in hippocampal
neurons that lack ubiquitin pathology
Strong aSN immunoreactivity could be observed in perikarya
and dendrites, mainly in the CA3 region of the hippocampus
(Figure 4A). Immunostaining with anti-P-Ser129aSN showed the
abundant presence of the phosphorylated form of aSN in many
neurons and throughout brain regions where the transgene is
expressed (Figure 4B,C). In the hippocampus, a significant subset
of neurons showed perikaryal and dendritic accumulation of aSN
(Figure 4C). The more striking observation was that in CA1 and
CA3 hippocampal neurons, when co-immunolabeled for aSN and
P-Ser129aSN, the latter was prominently localized in the nucleus
(Figure 4C). Similar to a previous study [6], the hippocampus
lacked neurons immuno-positive for ubiquitin (not shown). Also in
cortex only very few neurons showed ubiquitin pathology and/or a
perikaryal accumulation of aSN (Figure 4E,H).
Non-overlapping phosphorylated aSN and ubiquitin
puncta along neuronal processes
Double labeling for ubiquitin and P-Ser129aSN was carried out
in paraffin sections of neurons in regions such as the cortex, where
only very few cells stained for ubiquitin (Figure 4D–I) and
additionally in regions with pronounced ubiquitin pathology such
as brainstem, colliculus and spinal cord (not shown). This revealed
an extraordinary staining pattern, in particular, in processes. As
shown, P-Ser129aSN and ubiquitin immunopositive stretches in
processes alternate and did not overlap (Figure 4J). In contrast, in
cell somata, the distribution patterns of P-Ser129aSN and
ubiquitin were strikingly similar and overlaped to a high extent
(Figure 4D–I).
Thy1-maSN mice displayed abnormal mitochondria,
demyelination, axonal loss and non-fibrillar amorphous
aggregates
Enlargedmitochondriaareasign ofcellstryingtocompensatefor
energy deficits, reflecting local increases in the need for energy,
vacuolization and/or loss of inner-outer membrane integrity of the
Figure 2. Behaviour analysis of Thy1-maSN mice. (A) Measurement of the velocity and the total distance (B) in the open field paradigm
revealed no change between Thy1-maSN (+/T, black, n=10) and wildtype (wt, white, n=10) mice. (C) No difference in the forelimb grip strength
between Thy1-maSN and wt mice. (D) At the age of 28 weeks we observed a decline in performance of Thy1-maSN (+/T, black line) compared to wt
(dotted line) mice assessed by the accelerating rotarod. (E) Thy1-maSN mice show similar activity pattern as wt mice over a period of 48 h (dark
periods are indicated). (F) Quantification of the latency of the first entry to the dark compartment and of the time spent in the lit compartment in the
dark/light box in 5 min. Thy1-maSN and wt. (G) Measurement of the latency of the first entry to the open arms and the time spent in the open arms
of the elevated plus-maze in 5 min. Thy1-maSN and wt. Age of the animals: 6 months. Data are shown as mean 6 SEM (n=12). * p,0.05.
doi:10.1371/journal.pone.0024834.g002
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abnormal high number of cristae but without any obvious
vacuolization in spinal cord dendrites of Thy1-maSN mice
(Figure 5A). Spinal cord axonal degeneration was also evident by
an accumulation of pathological organelles (including mitochon-
dria) in the axoplasma (Figure 5B) with disappearance of the axon,
loosening of the myelin wraps and vesicular disruption of the myelin
sheath (Figure 5C). Interestingly, the axon showed pronounced
beading with focal anti-P-Ser129aSN staining on a background of
diffuse aSN immunostaining (Figure 5D). Immunoelectron
microscopy (10 nm immunogold) showed P-Ser129aSN antibody-
negative immunostained neurofilaments with side-branches pro-
truding from the filaments in Thy1-maSN (Figure 5E). We found
that aSN over-expression results in short, thick, and less well
oriented filaments of approximately 10 nm in diameter. They were
devoid of side-branches, focally decorated by gold particles and
coincide with non-fibrillar amorphous aggregates (Figure 5E,F)
similar as the granular aggregates found in Thy1-haSN mice [6].
To provide biochemical evidence for the observed aggregation
of aSN in Thy1-maSN mice, we perfomed solubility assays (see
[13]). Brainstems from 3–5 mice were pooled, yielding matched
starting tissue wet weight of 0.2 g. Tissue was homogenized in Tris
buffer, and the buffer-insoluble material was dissolved in 1%
Triton X-100. Such fractions were immunoblotted and probed
with anti-aSN. The endogenous aSN from wt mice was mostly
recovered in the buffer-soluble fraction, as expected (Figure 6).
Transgenic mice showed the increased expression of aSN in the
buffer-soluble fraction. In addition, Thy1-maSN mouse tissues
contained also buffer-insoluble aSN (Figure 6). Importantly, and
consistent with the age-dependent aggravation of neuropathology
(see above), the amount of buffer-insoluble aSN increased when
comparing 2–3 months with 5–6 months old mice (Figure 6A).
Thus, the increase of insoluble aSN in these mouse brains was not
simply due to higher total aSN expression, but seems to indicate a
shift towards insolubility with age. The amounts of soluble and
insoluble aSN in 5–6 months old heterozygous Thy1-maSN
Figure 3. Pathology in Thy1-maSN mouse spinal cord. (A–D) Correspond to sections through the anterior horn. Prominent perikaryal and
neuritic maSN staining (5038, Chemicon) in Thy1-maSN (+/T) (A) but not in wildtype (wt) (B) mouse spinal cord section. Expression of endogenous
aSN, same antibody as in (A), is restricted to synaptic boutons in wt mice (B). Strong ubiquitin (Ub) immunolabeling in spinal motor neurons, some
with spindle-shaped dilatations of proximal dendrites (C). Some anti-P-Ser129aSN immunoreactive motor neurons and presynaptic boutons in
transgenic (D) but not wt mice (not shown). (E–H) representative images of the spinal cord white matter including spinal roots in longitudinal
sections (E,F) and cross sections (G,H). Many axons stained with anti-ubiquitin (Ub) (E). Holmes-Luxol stain depicting axonal degeneration in long
white matter tracts of the spinal cord and breakdown of myelin sheaths with ovoids (arrows) (F). Many spinal cord and root axons immunolabel using
anti-aSN antibody (5038, Chemicon) (G). A subset of central and peripheral axons was immunolabeled with anti-P-Ser129aSN antibody (H) that
showed no staining in wt mice (not shown). Central axons are often enlarged (G,H). (I) Cross-sectioned muscle fiber bundle with small angulated
fibers (arrows). (J–Q) Soleus neuromuscular junctions from wt (J–M) and Thy1-maSN (N–Q) mice. Neuromuscular junctions were stained with a-
bungarotoxin (aBT) to label postsynaptic acetycholine receptors (J,N), synaptophysin (synphys) (K,O), and neurofilament (NF) (L,P). Overlay of all
three colors is shown (M,Q).
doi:10.1371/journal.pone.0024834.g003
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heterozygous Thy1-h[A53T]aSN mice (Figure 6B).
No SDS-PAGE resistant higher molecular weight smears were
detected in the insoluble fractions. Further analysis of the
detergent-insoluble material showed no detectable aSN in sarcosyl
extracts (not shown), where fibrillar ‘‘amyloid’’ aSN would be
expected. Taken together, the histological and biochemical
analyses revealed insoluble, non-fibrillar aggregates in Thy1-
maSN mouse brains.
Various post-translational modified aSN isoforms
expressed in neurons of Thy1-maSN mice
Isoelectric focusing Western blotting using several antibodies
were performed to characterize the aSN isoforms expressed in the
brain of Thy1-maSN mice (Figure 7). We found a novel aSN
isoform specific to colliculus and brainstem, the two regions with
extensive ubiquitin pathology (Figure 7A,B,D). Importantly the
novel P-Ser129aSN isoform is not detected using aSN antibodies
targeting the C-terminus (Fig. 7C,E) and additionally not present
in previously characterized mouse lines expressing haSN [6]
(Figure 7F).
Summarizing the expression of maSN isoforms in mice showed
pronounced ubiquitin immunopathology in spinal cord including
a novel aSN isoform. Additionally, we observed a strong aSN
pathology in the spinal cord accompanied with axonal degener-
ation. These findings were followed by signs of presynaptic
degeneration with reduced neurofilament staining in neuromus-
cular junction synapses. Interestingly, hippocampal neurons
showed strong aSN accumulation but no ubiquitination in
contrast to spinal cord motor neurons. Furthermore, we showed
that few neurons in the cortex display an intriguing staining
pattern of ubiquitin and phosphorylated maSN, suggesting that
these posttranslational modifications play a role in trafficking and
localization of aSN.
Figure 4. Co-localisation of Ubiquitinated and Phosphorylated maSN. (A–C) confocal images of immunostains for aSN (S63320,
Transduction Labs) (A), P-Ser129aSN (B) and the high power overlay (C) in adult Thy1-maSN mouse hippocampus. (D–I) Confocal images of two P-
Ser129aSN (D,G) and Ubiquitin (Ub)-immunopositive neocortical neurons (E,H) showing overlapping distribution patterns in cell soma (F,I), but a
largely non-overlapping distribution pattern of the epitopes in processes as highlighted by the enlargement (J). The broken arrow indicates an Ub-
immunostained zone (red, Cy3), the solid arrow a flanking region on the same process that is strongly immunopositive for P-Ser129aSN (green, FITC).
doi:10.1371/journal.pone.0024834.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24834Figure 5. Ultrastuctural features of neurons in Thy1-maSN mice. (A) Section through the anterior horn of the spinal cord. (B) Spinal cord
white matter containing a cross-sectioned myelinated nerve fiber. (C) End-stage axonal degeneration. (D) detail of a longitudinal 4 mm thick paraffin
section through the spinal cord after dual labelling with affinity purified anti-aSN (red, 5038, Chemicon), and anti-P-Ser129aSN (blue). (E,F)
Immunoelectron microscopic images of white matter axons in the spinal cord in 6 months old Thy1-maSN animal. The dark particles are 10 nm
colloidal gold conjugated to the P-Ser129aSN-specific antibody. (E) In the right side of the photograph are negatively stained neurofilaments, arrow-
head shows side-branches protruding from the filaments. Seen on the left are filaments focally decorated by gold particles and devoid of side-
branches, arrows show non-fibrillar amorphous aggregates, as shown in greater detail in F. Scale bars: A, 1.7 mm (4,5006magnification); B, 0.4 mm
(20,0006magnification); C, 0.6 mm (12,0006magnification); D, 20 mm (1006magnification); E–F, 0.25 mm (30,0006magnification).
doi:10.1371/journal.pone.0024834.g005
Figure 6. Solubility assays of Thy1-maSN mouse brain tissue. Pooled frozen brainstems from 3-5 mice (equal 0.2 g wet weight) were
homogenized in Tris buffer. Cleared supernatant were centrifuged for 20 min at 350.0006g. The buffer-soluble supernatants were loaded directly
(‘‘soluble’’). Pellets were dissolved in Tris buffer containing 1% Triton X-100. After another centrifugation for 20 min at 350.0006g, the supernatants
were loaded (‘‘insoluble’’). Western blots were prepared and probed with anti- aSN. (A) Samples from average 2.4 months old wildtype littermate
mice (+/+) showed the endogenous aSN band in the buffer-soluble fractions. In addition, heterozygous Thy1-maSN mice (+/T) showed aSN
monomeric bands also in the buffer-insoluble fractions. Older (average 5.4 months old) mice showed more aSN in the Triton X-100 fraction than
young (average 2.1 months old) mice. (B) The amounts of soluble and insoluble aSN in 5–6 months old heterozygous Thy1-maSN mouse brain
samples were comparable to those in age-matched heterozygous Thy1-h[A53T]aSN mice. Positions of molecular weight markers are indicated to the
left, purified recombinant aSN (10 ng) yielded control signals and co-migrated with the brain-derived bands. Results are representative of 3
independent extractions involving a total number of 42 mice (A) and 2 independent extractions with 17 mice total (B), respectively.
doi:10.1371/journal.pone.0024834.g006
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24834Figure 7. Isoelectric focusing Western blot analysis of aSN isoforms. (A–F) Each panel shows the immunoblot analysis of 12 brain protein
samples fractionated by isolectric focusing on a pH 4.5–5.4 gradient. Bars cover four lanes representing the same mouse. Lanes 1–4, wildtype (wt)
mouse brain. Lanes 5–8, Thy1-maSN mouse brain. Lanes 9–12, Thy1-h[A53T]aSN mouse brain [6]. Lanes 1, 5, and 9 are protein homogenates from
cortex. Lanes 2,6,10, hippocampus. Lanes 3,7,11, colliculus. Lanes 4,8,12, brainstem. After isolelectric focusing, aSN isoforms were visualized using the
following 4 different antibodies: (A) anti-aSN (Syn-1, S63320, Transduction Labs), (B) anti-aSN (4D6, Abcam), (C) anti-aSN (5038, Chemicon), (D) anti-
P-Ser129 aSN (WAKO), (E) anti-mouse aSN-specific Ab [5] and (F) for comparison, an anti-human aSN-specific antibody that fails to recognize mouse
aSN (Syn211, Zymed). The arrows indicate a novel aSN isoform specific to colliculus and brainstem.
doi:10.1371/journal.pone.0024834.g007
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Transgenic animals are considered excellent preclinical models
to study a-synuclein (aSN) disease pathophysiology and test
therapeutic strategies. Here we show that wildtype murine aSN
can induce pathological changes in mouse brain closely resembling
those observed in post-mortem human PD and DLB brains. These
transgenic mice are very similar to those over-expressing human
wildtype or the familial PD point-mutated A53T aSN [6]. Van der
Putten et al. used the same Thy1 promoter to drive comparable
aSN levels in similar brain regions compared to our Thy1-maSN
transgenic mice. This is very intriguing since for the first time we
show that murine aSN as well as human aSN can be pathogenic in
neurons in vivo.
Interestingly, profound neuropathological changes could be
detected solely in spinal cord, brainstem and cerebellum (after six
months of age). Forebrain areas were always histopathologically
unaffected despite a strong murine aSN over-expression. We show
that neurons in the forebrain (like CA1 pyramidal cell) displayed
the same strong somatic aSN staining as cells in the brainstem and
cerebellum. Thus, this abnormal somatic accumulation of aSN
does not account for the difference of histopathology observed for
the different brain areas leading to the conclusion that rather the
endogenous ‘normal’ aSN expression pattern might be responsible
for the different neuronal vulnerability. For example, in wildtype
(wt) animals, aSN is highly expressed in forebrain regions
compared to brainstem and cerebellum. This suggests that
neurons with low endogenous aSN levels are more sensitive to
over-expression of aSN at a certain age. Unfortunately, the short
life expectancy of Thy1-maSN mice hindered a possible
histopathology in the forebrain later in development. A fore-
brain-specific expression (e.g. aCamKII) could unravel this issue.
In solution aSN is natively unfolded, whereas the acidic
phospholipids are a-helical in nature. In cells, the structure of
aSN is highly dynamic forming equilibrium between oligomers, b-
sheets and large aggrosomes that is context dependent [15,16]. We
observed in brains of Thy1-maSN (,6 months of age) several
isoforms of maSN whereas one of it was specifically restricted to
brainstem and colliculus, areas of late-onset neuropathology. This
specific isoform was Ser129-phosphorylated (P-Ser129aSN) and
notably, could be detected before the appearance of any
immunopathology. Moreover, this specific isoform could not be
detected with antibodies targeting the C-terminus, which might be
due to the heavy phosphorylation of this isoform that hindered
antibody binding. Brain areas without any late-stage histopathol-
ogy were devoid of this isoform, while the abundance of other
isoforms was unchanged. The identification of the sequence of this
isoform might give more insights about its function and its
involvement in the neuropathological process.
However, we could not observe any brain area specific isoform
in mice over-expressing haSN which could merely be related to
the antibodies used. Thus, the P-Ser129aSN isoform could be
attributed to the brain area-specific late-onset neuropathology
observed in Thy1-maSN mice. Soluble forms of aSN, aSN fibrils
and protofibrils, soluble protein complexes of aSN with 14-3-3
protein, phosphorylated, nitrosylated, and ubiquitinated aSN
species have all been implicated in neurotoxicity [2,17].
There is a cause-and-effect relationship between Ser129-
phosphorylation of aSN and the disease. Noted in several animal
models was an accumulation of Ser129-hyperphosphorylated,
nitrosylated, ubiquitinated, and/or fragmented aSN species
[6,7,8,9,13,18]. P-Ser129aSN yields more insoluble sediments
and oligomers as compared to its non-phosphorylated counterpart.
Moreover, the aSN pathology in human brain, transgenic mouse
brain and transgenic fly neurons are enriched in Ser129-
hyperphosphorylated aSN [10,13,19,20]. Our current findings
suggest that Ser129-phosphorylation of aSN by itself is not
sufficient to cause aSN pathology in neurons in vivo. We found that
over-expression of wildtype maSN greatly enhanced levels of P-
Ser129aSN in different brain regions, but only some of these
regions show cellular hallmarks of aSN pathology. Posttransla-
tional modification of Ser129 by phosphorylation seems therefore
part, but not the whole reason to convert the aSN molecule into
toxic entities. Transgene expression of a phosphorylation-defective
Ser129 substitution mutant Ala129 is now needed to experimen-
tally confirm this hypothesis.
In several transgenic models aSN causes an impairment of
neuronal function and the development of aSN micro and/or
macro aggregates (amorphous, granular and/or fibrillar). Some
have been shown to be proteinase-resistant aSN aggregates [13].
The pathology has been observed in synapses, axons, dendrites
and neuronal cell somata. Occasionally, there was also inclusion
formation in glia. However, in the majority of transgenic rodent
models aSN aggregates appeared non-fibrillar, granular and/or
amorphous at the electron microscopic level [13]. This is in line
with our observations of non-fibrillary amorphous aggregates.
Biochemical extractions did show an age-dependent shift into
buffer-insoluble fractions, but no detergent resistance of aSN in
Thy1-maSN mouse brains. Rarely, investigators have reported
fibrillar aSN structures similar to filamentous aSN observed
in human samples [7,13]. Altogether the findings seem to
suggest that fibrillar, as well as other types of aSN aggregates,
are associated with pathophysiological effects of aSN in vivo
[6,8,9,18].
Phosphorylated mono- and di-ubiquitinated aSN forms exist
in human brains with a-synucleinopathy suggesting that phos-
phorylated aSN is targeted to mono- and di-ubiquitination [4].
UCH-L1 and/or Parkin mediated ubiquitination of aSN could
control its function, catabolism/stability, localization and interac-
tion with other molecules and levels of toxic protofibrils, although
knock-out of UCH-L1 in Thy1-maSN had no effect on aSN
metabolism and localization (unpublished observation). Ubiquiti-
nation in Thy1-maSN transgenic mice was evident along with the
other histopathologies in every mouse that we analysed and was
restricted to brainstem, cerebellum and spinal cord. This is in
contrast to mice over-expressing the human form of aSN showing
ubiquitination only sporadically [6]. The amino-acid sequence of
human and mouse aSN are very similar and differ only at seven
positions. This includes position 53, where in wildtype mouse aSN
the amino-acid threonine instead of alanine is present. The human
pathogenic mutation A53T hence naturally exists in mouse and
thus, cannot account for the difference observed in ubiquitination
in mice over-expressing wildtype mouse and human A53T point-
mutated aSN. This suggests that rather the six other amino-acid
differences between human and mouse that are located down-
stream of position 53 guide the ubiquitin pathology. In human
brains, ubiquitinated structures represent mainly classical Lewy
bodies and Lewy neurites [21]. However, the brain areas positive
for strong ubiquitination in our mice did not display any enhanced
degree of aSN aggregation. This indicates that ubiquitination
might not be required for the formation aSN inclusions as
described elsewhere [22].
Mice over-expressing murine wildtype aSN showed no early
motor deficits aside from minor motor learning impairment.
Motor impairments are not obvious until 6 months of age that
coincide with a rapid decline in health, resulting in death of the
animal. This is in sharp contrast to mice over-expressing human
aSN displaying early-onset motor deficits. Hence, murine aSN in
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interfere with normal neuronal function in early development.
All Thy1-maSN animals analysed developed alongside these
motor deficits degeneration of the NMJ, astrogliosis, microgliosis,
axonal and ubiquitin pathology. Classical Lewy body-like
structures were not observed. Unfortunately, the Thy1 promoter
fails to express in dopaminergic neurons (data not shown) and
thus, no pathology in the substantia nigra pars compacta could be
observed. Although, these cells in the human brain are most
sensitive to develop Lewy pathology, and the resulting nigral
lesions are primarily involved in the clinical symptoms of PD
[23,24,25,26], extranigral Lewy pathology is very common in PD
and LBD brains [23,27,28,29].
Moving towards disease-modifying therapies requires a general
understanding of the role of (epi)genetic and environmental
factors. Moreover, insights into the presymptomatic/symptomatic
changes and of the molecular identity of the culprit(s) and
pathway(s) that drive disease process are necessary. We also need
diagnostic tools, biomarkers and translational animal models that
mimic aSN-induced pathophysiological changes and allow testing
of the effects of drugs, antibodies, genes and RNAi that halt and/
or reverse disease. Human mutant, human wt, and mouse wt aSN
drive disease pathophysiology and loss of neuronal cell function.
These transgenic mice display many hallmark features of human
pathology and provide means to address fundamental aspects of
disease pathophysiology, explore surrogate markers, test thera-
peutic strategies with behavioural and biochemical read-outs and
provide a good model for extra-nigral a-synucleinopathy.
Materials and Methods
Statement on Animal Health
All experiments were carried out in accordance with authori-
zation guidelines of the Swiss Federal and Cantonal veterinary
offices for care and use of laboratory animals. Studies described in
this report were approved by the Swiss Cantonal veterinary office
and performed according to Novartis animal license number 2063.
Transgenic mice
Wildtype mouse a-synuclein cDNA (531 bp) was PCR amplified
(2 min. 93uC; 3 cycles of 15 sec, 93uC; 30 sec, 55uC; 30 sec, 72uC;
2 cycles of 15 sec, 93uC; 30 sec, 60uC; 30 sec, 72uC; and 30 cycles:
15 sec, 93uC; 30 sec, 66uC; 30 sec, 72uC; oligonucleotides GGGA-
GCCGTGTGGAGCAAAAATAC and TGGGCACATTGGAA-
CTGAGCACTT) from 20 ng C57BL/6 brain cDNA (in-house
C57BL/6 strain) and cloned into pMOSBlue (Amersham, UK).
The identity of the cDNA was confirmed by sequencing and the
corresponding blunted (Klenow) cDNAs (NotI) inserted into the
blunted (XhoI site) Thy1 cassette [6,30]. For microinjection, linear
NotI DNA fragments comprising transgene without plasmid vector
sequences were isolated. Injection was into homozygous C57BL/6
mouse eggs. Genotyping was performed by PCR (oligonucleotides
HP45 Thy1 sense (59-ACA CCC CTA AAG CAT ACA GTC
AGA CC-39) and HP42 aSN antisense (59- TGG GCA CAT TGG
AAC TGA GCA CTT-39); 5 min 95uC, 35 cycles of 30 s 95uC,
40 sec 62uC, 40 sec 72uC, 10 min. at 72uC) with standard pro-
cedures using column-purified (Qiagen) tail DNA. Expected band
size of the transgene: 1200 bp.
Northern blot analysis
Northern blot analysis was carried out with total brain RNA
(TriZol method; 10 mg loaded per gel lane). Blots were probed
with a full length (449 bp) mouse a-synuclein cDNA using
standard procedures.
In Situ hybridization
The spatial distribution pattern of transgene versus endogenous
a-synuclein expression was determined by in situ hybridization as
described before [6] using cRNA derived from a 449 bp complete
coding cDNA template of mouse a-synuclein.
Western blot and isoelectric focusing (IEF) analysis
For standard SDS-PAGE Western blot analysis, 14.0006 g
supernatant fractions were used of half-brain homogenates
(homogenized in 2 ml E-buffer; 50 mM Tris-HCl, pH 7.4, 1%
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, a
cocktail of protease inhibitors (Boehringer Mannheim), and left on
ice for 30 min). 50 mg protein was loaded per lane and separated
on 15% SDS-PAGE. After blotting and blocking non-specific
binding, membranes were incubated with monoclonal anti-a-
synuclein antibody (1:1000; Syn-1, S63320, Transduction Labo-
ratories), followed by HRP-conjugated anti-mouse IgG (1:1000,
RPN2108, Amersham), and ECL western blotting detection
reagents (RPN2108, Amersham).
For solubility assays, pooled frozen brainstems (matching 0.2 g
starting wet weight) were homogenized in 10 volumes buffer A
(50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol)
using a Teflon potter. The homogenate was cleared by
centrifugation for 10 min at 10006g. Cleared homogenates were
centrifuged for 20 min at 350,0006g. The buffer-insoluble pellets
were resuspended in buffer A+1% Triton X-100, followed by
another centrifugation for 20 min at 350,0006 g. All steps were
carried out on ice. Preparation of purifed recombinant aSN
control protein was described elsewhere [31]. Samples were boiled
in La ¨mmli buffer and subjected to denaturing 12.5% polyacryl-
amide gel electrophoresis. Western blots were prepared and
probed with monoclonal anti-aSN (1:250; Transduction Labora-
tories). Ponceau red staining of the polyvinylidene fluoride
membranes confirmed equal loading.
For IEF Western blot analysis, brain samples were homogenized
in a buffer [32] containing 4% CHAPS, 7 M urea, 2 M thiourea,
10 mg/mL dithiothreitol, and 1% carrier ampholytes (pH 3–10;
Pharmalytes; Amersham Pharmacia Biotech, Uppsala, Sweden).
Isoelectric focusing on immobilized pH gradient plates (pH range
4.5–5.4, Amersham Pharmacia), transfer to PVDFmembranes, and
immunodetection was carried out as described [33]. The protocol
included a trichloroacetic acid wash step and formaldehyde fixation
of the transferred proteins [33]. Protein extracts were adjusted to
10 mg/ml and 1 ml loaded per lane. Bound antibodies were detected
by peroxidase conjugates against rabbit IgG (1:2000, NA934V, GE
Healthcare), mouse IgG (1:2000, NA931V, GE Healthcare), or an
alkaline phosphatase conjugate against sheep IgG (1:5000; Jackson
ImmunoResearch 313 055 033). ECL Western blotting detection
reagents for peroxidase (Amersham Pharmacia RPN2109) or Lumi-
PhosWBforphosphatase(Pierce 34150)wereused forvisualization.
Antibodies used: mouse anti-aSN (Syn-1, S63320, Transduction
Labs), mouse anti-aSN (4D6, Abcam), rabbit anti-aSN (5038,
Chemicon), mouse anti-P-Ser129aSN (WAKO), anti-mouse aSN-
specific Ab [5] and anti-human aSN-specific antibody (Syn211,
Zymed).
Immunohistochemistry
Mice (age 1.5–8 months) were perfused transcardially with
0.01 M phosphate buffered saline (PBS) followed by 4%
paraformaldehyde in PBS. Brain, spinal cord and hind limb
muscle were embedded in paraffin and cut as 4 mm thick sections
or 25 mm vibratome sections were cut of the brain for free floating
immunohistochemical staining using mouse anti-a-synuclein
antibodies (Syn-1, 1:500; S63320, Transduction Laboratories
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AB5038, Chemicon), mouse anti-P-Ser129 a-synuclein (1:20000,
WAKO), biotinylated anti-mouse IgG (1:500; E0464, Dako) and
avidin-biotin peroxidase method (Elite standard kit SK6100,
Vector). Deparaffinized sections were used for Campbell Switzer
silver staining and immunostaining with rabbit anti-ubiquitin Ig
fraction (1:200; Z0458, Dako). Antigenity was enhanced by
treating paraffin sections with concentrated formic acid for
5 min and microwave heating at 90uC for 60 min before
incubation with anti-a-synuclein; microwave heating at 90uC for
30 min before anti-GFAP and anti-phosphotyrosine anti-ubiquitin
treatment at 37uC, 30 min. Non-specific binding sites were
blocked using normal serum. Bound antibody was visualized
using avidin-biotin peroxidase method (Elite standard kit SK6100,
Vector) and DAB substrate (1718096 Boehringer), Vector VIP
substrate (SK-4600, Vector) or with fluroescence-labeled second-
ary antibodies (FITC or Cy3-labeled goat anti-mouse, FITC or
Cy3-labeled goat anti-rabbit, Jackson ImmunoResearch).
Immunostaining and confocal analysis of neurofilament and
synaptophysin at neuromuscular junctions (NMJs) were as follows.
Mice were killed by anaesthesia. Extensor digitorum longus (EDL)
and soleus muscle were stained with Alexa Fluor 488-labeled a-
bungarotoxin (1:200, Molecular Probes) for 30 min, washed with
PBS (3615 min) and fixedwith1.5% paraformaldehydefor10 min.
Muscles were teased into approximately 20 thin bundles and
permeabilized with 1% Triton X-100 in PBS for 1 h. Bundles were
treated with 100 mM glycine in PBS, followed by ‘‘blocking
solution’’ of 1% BSA in PBS, for 30 min. Then, they were
incubated overnight at 4uC with a mixture of primary antibodies
against synaptophysin (1:200, DAKO) and neurofilament (1:1000,
MAB 1621, Chemicon) in blocking solution and washed three times
1 h inblocking solution.The bundles wereincubated witha mixture
of Cy3-labeled goat anti-mouse IgG (1:1000, Jackson ImmunoR-
esearch) and Cy5-labeled goat anti-rabbit IgG (1:500, Jackson
ImmunoResearch) in blocking solution for 45 min at rommtem-
perature. After washing three times for 1 h with blocking solution,
bundles were mounted on glass slides using Citifluor (Plano), and
examined with a confocal microscope (Leica TCN NT).
Immunoelectron and electron microscopy
For immunoelectron microscopy, transgenic and wildtype
C57Bl/6 mice were perfused transcardially with a mixture of
1.5% picric acid, 0.1% glutaraldehyde, and 4% paraformaldehyde
in 0.1 Mphosphate buffer, pH 7.4. Vibratome sections were
stained free-floating with antibody to P-Ser129 a-synuclein
(1:2000, anti-P-Ser129 a-synuclein, WAKO) dehydrated in
ascending series of ethanol and acetone, and flat-embedded
between glass slide and coverslip in Embed-812 (Electron
Microscopy Sciences). Fragments of the spinal cord were then
dissected out and ultra-thin sections were cut from the tissue
surface, and these were mounted on copper grids and analyzed
with a microscope (EM900, Zeiss). For conventional electron
microscopy, mice were anesthetized and perfused transcardially
with cold saline, followed by 4% paraformaldehyde and 0.1%
glutaraldehyde in 0.1 M cacodylate buffer. Small tissue blocks
were cut out from brainstem and spinal cord, immersion-fixed for
12 h at 4uC in the same buffer, and epoxy-embedded, and ultra-
thin sections were prepared and placed on 200-mesh copper grids
for staining with uranyl acetate and lead citrate.
Behavior
Rotarod. To measure motor coordination mice were placed
on a computerized treadmill (TSE rotarod system, Germany). The
rotarod program consists of accelerating running speed from
5 rpm to 36 rpm in 5 min. Rotarod performance was assessed by
evaluating the two best trials out of three performed in one day.
The 3-step rotarod consists of a modified rotarod program of three
different running speeds (12 rpm, 24 rpm and 36 rpm) each for
30 sec with intervals of acceleration lasting for 10 sec. Starting
speed is 4 rpm. Rotarod performance was assessed by evaluating
the two best trials out of three performed in one day.
Grip strength. To measure forelimb grip strength, mice are
allowed to grasp a handle connected to a force-measuring device
(San Diego Instruments, USA) and then pulled back with their
tails until they release the handle. The best out of four consecutive
trials is evaluated.
Open field. To measure exploratory behavior (pattern and
activity), mice were placed in an open field box (70 cm670 cm,
height of walls: 30 cm) subdivided into nine quadrants with
one middle quandrant. The horizontal distance travelled during
5 min was recorded by an EthoVision 3.0 system (Noldus, The
Netherlands).Inadditionthenumberofrearingswasdetermined by
visual inspection.
Actimeter. Recordings were made in automated circular
corridors (Imetronic, France) for 48 h. These corridors with a
radius of 4.5 cm and a width of 5.3 cm were equipped with 4
photocells, equidistant of 7 cm and 45u from each other, connected
to an electronic interface, itself connected to a computer. Motor
activity corresponds to the number of photocell interruption per
time unit (20 min) and locomotor activity corresponds to the
number of quarter turns corresponding to the successive
interruption of two photocells. The dark and light phases lasted
12 h each.
Dark/light box. The dark/light box consists of a dark and a
bright compartment. Mice were placed in the bright compartment
and given the opportunity to move to the dark box for 5 min.
Parameters measured by EthoVision 3.0 (Noldus, The
Netherlands) were the time spent in the bright compartment and
the latency of first entry to the dark compartment. The number of
transitions and the latency of first exit back to the bright
compartment were measured visually.
Elevated plus-maze. The elevated plus-maze (80 cm from
the floor) consists of four arms (length: 27 cm) arranged in right
angles to each other. Two opposite arms have walls (height: 15 cm)
and the two others are open. Mice are placed in the middle and are
allowedto move freelyfor5 min. Thetime spentinthe open arms is
recorded by EthoVision 3.0 (Noldus, The Netherlands) and the
number of entries to open arms by visual inspection.
Maintenance
The animals were housed in a temperature-controlled room
that was maintained on a 12 h light/dark cycle. Food and water
were available ad libitum.
Supporting Information
Figure S1 Bodyweight and behaviour analysis of Thy1-
h[A53T]aSN transgenic mice. (A) Body weight assessment in
Thy1-h[A53T]aSN (+/T, black) and littermate wildtype (wt)
controls (white); n=12. Thy1-h[A53T]aSN mice show reduced
behavior activity as measured by total distance (B) and velocity (C)
in the open field paradigm. (D) Strong reduction of forelimb grip
strength in Thy1-h[A53T]aSN compared to wt mice. (E)
Measurement of the performance on the 3-step rotarod reveals
strong locomotor impairment of Thy1-h[A53T]aSN mice. (F)
Quantification of the latency of the first entry to the dark and of
the time spent in the lit compartment in the dark/light box in
5 min. (G) Measurement of the latency of the first entry to the dark
Overexpression of Mouse Alpha-Synuclein
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24834and of the time spent in the lit compartment in the dark/light box
in 5 min. Age of the animals: 2–3 months. Data are shown as
mean 6 SEM (n=10). * p,0.05; ** p,0.01; *** p,0.001.
(TIF)
Figure S2 Increased aSN accumulation in Thy1-maSN
transgenic mice. (A–D) Prominent aSN immunoreactivity in
CA1 (A,C) and cerebellar nuclei (B,D) at different ages (1.5 and 3
months old) compared to low aSN immunoreactivity in wildtype
(wt) littermates (3 months) (E,F).
(TIF)
Figure S3 Transgene and endogenous maSN protein
expression in hippocampus. (A–D) Immunofluorescence
images of maSN protein detected in 25 mm thick free-floating
sagittal hippocampal sections of a wildtype (wt) mouse (A), a Thy1-
maSN mouse (B), a aSN KO mouse (C) and a Thy1-maSN
transgene after crossing into the aSN knock-out (KO) genetic
background (D).
(TIF)
Figure S4 Thy1-maSN transgenic mice show increased
inflammation. (A,B) Immunoperoxidase stained sagittal sec-
tions of GFAP from wildtype (wt) (A) and Thy1-maSN (+/T) (B)
mice. (C–K) high power magnification of pontine nuclei stained
GFAP (C,D), Iba1 (F,G) and Campbell (I,J) and the quantifica-
tion respectively (E,H,K). Data are shown as mean 6 SEM
(n=6); ** p,0.01; *** p,0.001.
(TIF)
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